Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation

Inge M. van der Sluis, Lynda M. Vrooman, Rob Pieters, Andre Baruchel, Gabriele Escherich, Nicholas Goulden, Veerle Mondelaers, Jose Sanchez de Toledo, Carmelo Rizzari, Lewis B. Silverman, James A. Whitlock

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

162 Citaten (Scopus)

Samenvatting

L-asparaginase is an integral component of therapy for acute lymphoblastic leukemia. However, asparaginase-related complications, including the development of hypersensitivity reactions, can limit its use in individual patients. Of considerable concern in the setting of clinical allergy is the development of neutralizing antibodies and associated asparaginase inactivity. Also problematic in the use of asparaginase is the potential for the development of silent inactivation, with the formation of neutralizing antibodies and reduced asparaginase activity in the absence of a clinically evident allergic reaction. Here we present guidelines for the identification and management of clinical hypersensitivity and silent inactivation with Escherichia coli- and Erwinia chrysanthemi- derived asparaginase preparations. These guidelines were developed by a consensus panel of experts following a review of the available published data. We provide a consensus of expert opinions on the role of serum asparaginase level assessment, indications for switching asparaginase preparation, and monitoring after change in asparaginase preparation.

Originele taal-2Engels
Pagina's (van-tot)279-285
Aantal pagina's7
TijdschriftHaematologica
Volume101
Nummer van het tijdschrift3
DOI's
StatusGepubliceerd - 2016

Vingerafdruk

Duik in de onderzoeksthema's van 'Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation'. Samen vormen ze een unieke vingerafdruk.

Citeer dit